Want to see GB:IMM full AI Analyst Report?
ImmuPharma (IMM) AI Stock Analysis
ImmuPharma
(LSE:IMM)
The score is driven primarily by very weak financial performance, including persistent losses, no revenue, negative cash flow, and a fragile capital base. Weak technical positioning and unfavorable valuation provide additional pressure, while no earnings-call or corporate-event data was available to influence the assessment.
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 20.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.15M
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 0.83
- Revenue Growth
- ―
- EPS Growth
- 5.62%
- Country
- UK
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead p...
How the Company Makes Money
ImmuPharma’s business model is primarily based on developing pharmaceutical assets and monetizing them through transactions such as licensing, co-development agreements, and/or commercialization partnerships, rather than operating a large, fully inte...
ImmuPharma Financial Statement Overview
Summary
Financial performance is very weak: the company is pre-revenue, persistently loss-making, cash-flow negative, and reliant on external financing. Minimal debt provides some support, but the thin capital base and ongoing cash burn keep the score near the minimum.
Income Statement
24NegativeBalance Sheet
40NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 118.35K |
| Gross Profit | -7,271 | -35.30K | -63.88K | -37.61K | -118.00K | 118.35K |
| EBITDA | -3.55M | -2.51M | -2.61M | -3.02M | -2.91M | -8.70M |
| Net Income | -7.02M | -1.81M | -2.48M | -2.92M | -3.81M | -8.17M |
Balance Sheet | ||||||
| Total Assets | 3.10M | 1.88M | 977.01K | 2.72M | 3.97M | 6.00M |
| Cash, Cash Equivalents and Short-Term Investments | 695.84K | 1.35M | 236.90K | 208.48K | 667.81K | 1.65M |
| Total Debt | 0 | 0 | 0 | 0 | 111 | 700 |
| Total Liabilities | 1.28M | 1.19M | 1.52M | 1.67M | 1.45M | 1.58M |
| Stockholders Equity | 1.82M | 686.86K | -542.86K | 1.06M | 2.52M | 4.41M |
Cash Flow | ||||||
| Free Cash Flow | -2.77M | -2.37M | -1.77M | -1.36M | -2.45M | -4.88M |
| Operating Cash Flow | -2.76M | -2.37M | -1.77M | -1.36M | -2.35M | -4.83M |
| Investing Cash Flow | 3,962 | 6,911 | 1.29M | 188.76K | -77.42K | -50.28K |
| Financing Cash Flow | 3.05M | 3.43M | 500.02K | 722.10K | 1.55M | 702.05K |
ImmuPharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IMM, the sentiment is Negative. The current price of 3.25 is below the 20-day moving average (MA) of 3.72, below the 50-day MA of 3.61, and below the 200-day MA of 4.66, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.71 is Neutral, neither overbought nor oversold. The STOCH value of 22.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IMM.
ImmuPharma Peers Comparison
Overall Rating
GB:SBTX59Neutral
GB:SAR47Neutral
GB:POLB46Neutral
GB:SCLP43Neutral
GB:HEMO41Neutral- GB:IMM39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:SBTX | 59Neutral | GBP 13.61M | -29.17 | -5.25% | ― | 95.16% | 85.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:SAR | 47Neutral | GBP 25.36M | -6.25 | -188.01% | ― | ― | 28.78% |
| GB:POLB | 46Neutral | GBP 48.86M | -8.21 | -71.28% | ― | ― | 31.58% |
| GB:SCLP | 43Neutral | GBP 104.74M | -4.86 | 128.87% | ― | -100.00% | -30.39% |
| GB:HEMO | 41Neutral | GBP 44.14M | -3.34 | -409.57% | ― | ― | 18.57% |
| GB:IMM | 39Underperform | GBP 21.96M | -2.60 | -559.87% | ― | ― | 5.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:IMM | ImmuPharma plc | 3.25 | -7.25 | -69.00% | |
| GB:SAR | Sareum Holdings | 15.00 | 0.00 | 0.00% | |
| GB:SCLP | Scancell Holdings | 85.00 | -13.50 | -13.71% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 605.00 | -371.00 | -38.01% | |
| GB:SBTX | SkinBioTherapeutics plc | 5.25 | -12.25 | -70.00% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.40 | 2.75 | 75.34% |
ImmuPharma Corporate Events
ImmuPharma Advances Global Patent Strategy for P140 Autoimmune Precision Therapy
PositiveImmuPharma has filed an international Patent Cooperation Treaty application for its P140 precision medicine approach in autoimmune disease, specifically addressing patients with the Type M immune profile who show an enhanced likelihood of response. T...
ImmuPharma’s P140 Shows Promise in Preclinical MASH Study
PositiveImmuPharma has announced new peer‑reviewed research showing its peptide P140 demonstrates biological activity in a preclinical model of metabolic dysfunction‑associated steatohepatitis, a liver disease marked by inflammation and fibrosis....
ImmuPharma narrows operating loss as fundraising funds P140 and Kapiglucagon push
PositiveImmuPharma reported an operating loss of £1.1 million for the six months to 30 June 2026, broadly in line with the prior year, while a non-cash finance loss tied to revaluation of a derivative asset widened the overall loss to £4.7 million....
ImmuPharma taps Kymos as bioanalytical partner to advance Kapiglucagon diabetes programme
PositiveImmuPharma has appointed Kymos Group as the bioanalytical contract research partner for its Kapiglucagon programme, following a competitive tender, marking another key milestone in the drug’s non-clinical and early clinical development. The mov...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026